Shattuck Labs, Inc. (STTK) News
Follow Shattuck Labs, Inc. (STTK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
STTK: DR3-targeted therapies show durable efficacy and low immunogenicity, with broad expansion plans
The session highlighted a differentiated approach to immune modulation by targeting DR3, with promising phase I data showing durable receptor occupancy and low immunogenicity. Clinical development is focused on Crohn's d
EQUITY | Sep 09, 2026, 09:16 PM UTC
L
STTK: DR3-targeted therapies show promise for durable efficacy and low immunogenicity in immune diseases
The session highlighted a differentiated approach targeting DR3 for immune diseases, with lower immunogenicity and durable efficacy compared to TL1A antibodies. Phase II trials in Crohn's are underway, with plans to expa
EQUITY | Sep 09, 2026, 08:52 PM UTC
M
STTK advances DR3 blockade for IBD; induction data slated for H1 2028
STTK is advancing DR3 blockade as a differentiated IBD approach, targeting superior maintenance efficacy and lower immunogenicity versus TL1A and IL-23 therapies. Induction data are expected in H1 2028 as trials continue
EQUITY | Sep 08, 2026, 04:35 PM UTC
L
STTK DR3 blockade touts durable efficacy; Crohn’s data slated for 2028
STTK’s DR3 blockade for IBD is presented as having advantages in immunogenicity and target stability over TL1A, with SL-325 showing durable receptor occupancy and low ADA rates. Phase II Crohn’s data is expected in 2028.
EQUITY | Sep 08, 2026, 04:02 PM UTC
L
STTK - Shattuck Labs Announces Participation in Upcoming September Investor Conferences
STTK - Shattuck Labs Announces Participation in Upcoming September Investor Conferences
EQUITY | Sep 02, 2026, 08:06 PM UTC
L
STTK receives Strong Buy rating, $18 price target
Hammerstone MarketTalk issues a new Strong Buy rating on STTK with an $18 price target; no magnitude, timeframe, or catalyst details are provided.
EQUITY | Aug 24, 2026, 01:06 PM UTC
L
Raymond James initiates STTK at Strong Buy, $18.00 target
Raymond James initiates STTK with a Strong Buy rating and an $18.00 price target.
EQUITY | Aug 24, 2026, 11:59 AM UTC
L
SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: Truist upgraded PayPal (PYPL) to H
EQUITY | Jul 24, 2026, 01:34 PM UTC
L
STTK Initiated Overweight and $10 PT @ JPMC
STTK Initiated Overweight and $10 PT @ JPMC
EQUITY | Jul 24, 2026, 01:22 PM UTC
L
STTK Initiated Outperform W/$16.00 PT at Leerink
STTK Initiated Outperform W/$16.00 PT at Leerink
EQUITY | Jul 20, 2026, 11:49 AM UTC